Research programme: antibacterial therapeutics- Da Volterra

Drug Profile

Research programme: antibacterial therapeutics- Da Volterra

Alternative Names: DAV-121; DAV-210; DAV131

Latest Information Update: 15 Sep 2016

Price : $50

At a glance

  • Originator Da Volterra
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Bacteria replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections; Intestinal infections; Urinary tract infections

Most Recent Events

  • 15 Sep 2016 Pharmacodynamics data from a preclinical trial in Clostridium infections presented at the at ASM Microbe 2016 (ASM-2016)
  • 16 Jun 2016 Preclinical trials in Clostridium infections in France (PO)
  • 31 Dec 2015 Preclinical trials in Intestinal infections in France before December 2015 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top